Mevis Medical Solutions AG
XETRA:M3V
Intrinsic Value
MeVis Medical Solutions AG engages in the provision of software for the analysis and processing of image data. [ Read More ]
The intrinsic value of one
M3V
stock under the Base Case scenario is
34.73
EUR.
Compared to the current market price of 25.6 EUR,
Mevis Medical Solutions AG
is
Undervalued by 26%.
Mevis Medical Solutions AG's market capitalization is 46.6m EUR.
M3V stock price is 25.6 EUR.
M3V stock price (25.6 EUR) is 26% less than its Intrinsic Value (34.73 EUR).
M3V.
M3V's Revenue has grown by 16% over the past 12 months.
M3V's ROIC (Return on Invested Capital) has increased in the last 3 years from 25% to 31%.
M3V's short-term assets (15m EUR) exceed its short-term liabilties (10m EUR).
M3V's ROE (Return on Equity) has significantly increased in the last 3 years from 29% to 44%.
M3V's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 31%.
M3V has positive three-year average ROIC (Return on Invested Capital): 23%. The company is efficient at using invested capital to generate operating income.
M3V has positive Operating Income for the last twelve months.
M3V's ROE (Return on Equity) for the past 12 months is very high and is equal to 44%.
M3V has positive Net Income for the last twelve months.
M3V's long-term assets (31m EUR) exceed its long-term liabilties (13m EUR).
M3V has very high three-year average ROE (Return on Equity): 29%. The company is very efficient at transforming stockholders' equity into net income.
M3V has positive Gross Profit for the last twelve months.
M3V has positive Free Cash Flow for the last twelve months.
M3V's Altman Z-Score is very high and is equal to 4.11.
M3V's D/E (Debt to Equity) is very low and is equal to 0.
Valuation Backtest
Mevis Medical Solutions AG
Run backtest to discover the historical profit from buying and selling
M3V
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Mevis Medical Solutions AG
Balance Sheet Decomposition
Mevis Medical Solutions AG
| Current Assets | 14.5m |
| Cash & Short-Term Investments | 9.3m |
| Receivables | 4.7m |
| Other Current Assets | 443.9k |
| Non-Current Assets | 16.7m |
| Long-Term Investments | 312k |
| PP&E | 162k |
| Intangibles | 160 |
| Other Non-Current Assets | 16.2m |
| Current Liabilities | 9.7m |
| Accounts Payable | 192.6k |
| Other Current Liabilities | 9.5m |
| Non-Current Liabilities | 3.7m |
| Other Non-Current Liabilities | 3.7m |
Earnings Waterfall
Mevis Medical Solutions AG
|
Revenue
|
18.8m
EUR
|
|
Cost of Revenue
|
-746.6k
EUR
|
|
Gross Profit
|
18m
EUR
|
|
Operating Expenses
|
-11.5m
EUR
|
|
Operating Income
|
6.5m
EUR
|
|
Other Expenses
|
1.3m
EUR
|
|
Net Income
|
7.8m
EUR
|
Free Cash Flow Analysis
Mevis Medical Solutions AG
M3V Profitability Score
Profitability Due Diligence
Mevis Medical Solutions AG's profitability score is 76/100. The higher the profitability score, the more profitable the company is.
Score
Mevis Medical Solutions AG's profitability score is 76/100. The higher the profitability score, the more profitable the company is.
M3V Solvency Score
Solvency Due Diligence
Mevis Medical Solutions AG's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
Mevis Medical Solutions AG's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
M3V Price Targets Summary
Mevis Medical Solutions AG
Shareholder Return
M3V Price
Mevis Medical Solutions AG
| Average Annual Return | 5.66% |
| Standard Deviation of Annual Returns | 7.47% |
| Max Drawdown | -39% |
| Market Capitalization | 46.6m EUR |
| Shares Outstanding | 1 820 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Mevis Medical Solutions AG
Country
Industry
Market Cap
Dividend Yield
Description
MeVis Medical Solutions AG engages in the provision of software for the analysis and processing of image data. The company is headquartered in Bremen, Bremen and currently employs 103 full-time employees. The company went IPO on 2007-11-16. The firm develops medical application software for industrial customers including turnkey applications, and also research laboratories. In addition to that, the Company operates an online academy and trains professionals, such as radiologists, in working with its products. The firm's software applications support various applicable imaging modalities, especially magnetic resonance tomography (MRT) and digital mammography, but also computer tomography (CT), tomosynthesis and digital sonography based on ultrasonics.
Contact
IPO
Employees
Officers
The intrinsic value of one
M3V
stock under the Base Case scenario is
34.73
EUR.
Compared to the current market price of 25.6 EUR,
Mevis Medical Solutions AG
is
Undervalued by 26%.
You don't have any saved screeners yet
